V
Vessi Medical
Vessi Medical uses surface cryotherapy, a treatment that utilizes extreme cold, to freeze and destroy abnormal tissue in order to treat superficial bladder cancer
About Vessi Medical
Vessi Medical is a medical device company focused on the urological sector, specifically in the treatment of Non-Muscle-Invasive Bladder Cancer (NMIBC). The company has developed a proprietary system that utilizes surface cryotherapy, a process involving extreme cold, to ablate cancerous tissue within the bladder.
Read full description
The core of its offering is a minimally invasive cryospray system designed for use in hollow and humid organs. This technology provides a therapeutic alternative to traditional procedures for NMIBC. The treatment is delivered transurethrally, aiming to reduce the invasiveness of the procedure for the patient. The business model is centered on the development and commercialization of this medical device, targeting healthcare providers in the urology market. The company generates revenue through the sale of its cryotherapy systems and potentially recurring sales of disposables or related components.
Based in Israel, the company has secured funding to advance its technology, including a significant Series A round, indicating investor confidence in its approach to bladder cancer treatment.
At a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Misgav, Israel
- Employees
- 9
- Open positions
- 1
- Dealroom signal
- 74.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Surgery, Tissue Engineering, Surface, Surgical Equipment, Tech for Medical Professionals, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Vessi Medical.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Feb 2024 | $17M | $66M | ALIVE Israel HealthTech Fund · Agriline | ↗ |
| SEED✓Equity / VC | Aug 2020 | $1.7M | $6.8M | ExitValley · Agriline · Trendlines Group | — |
Growth signals
Latest recorded traffic for Vessi Medical is 580 monthly website visits, up 728.6% over the last three months. Vessi Medical's team grew 0% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
ExitValley
Agriline
Trendlines Group
Series A1 investor entered at this stage
ALIVE Israel HealthTech Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Vessi Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Vessi Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.